中草药
中草藥
중초약
CHINESE TRADITIONAL AND HERBAL DRUGS
2005年
11期
1671-1674
,共4页
田葆萍%张兰桐%袁志芳%刘伟娜%刘红菊
田葆萍%張蘭桐%袁誌芳%劉偉娜%劉紅菊
전보평%장란동%원지방%류위나%류홍국
马兜铃酸A%药动学%青木香%冠心苏合胶囊
馬兜鈴痠A%藥動學%青木香%冠心囌閤膠囊
마두령산A%약동학%청목향%관심소합효낭
aristolochic acid A%pharmacokinetics%Radix Aristolochiae%Guanxinsuhe Capsule
目的研究青木香及复方制剂冠心苏合胶囊中马兜铃酸A在小鼠体内的药动学特点及小鼠在ig给予含相同量马兜铃酸A的青木香和冠心苏合胶囊后,马兜铃酸A的吸收、分布规律的差异.方法采用RP-HPLC法测定血浆中马兜铃酸A的量.色谱条件:色谱柱为DiamonsilTMC18柱(250 mm×4.6 mm,5 μm),流动相为甲醇-水-冰醋酸(72:27 :1),体积流量为1.0 mL/min,检测波长为315 nm,柱温为20℃.结果药动学实验结果显示小鼠分别ig给予青木香和冠心苏合胶囊(相当于2.5 mg/kg马兜铃酸A)后,其体内的药动学房室模型均符合一室模型,青木香中马兜铃酸A主要药动学参数:t1/2ka、t1/2ke,tmax、AUC、Cmax分别为5.103 min、43.63 min、17.89 min、80.45(μg·min)/mL、0.916 8 μg/mL;冠心苏合胶囊中相应的参数分别为5.294 min、43.50min、18.32 min、33.08(μg·min)/mL、0.381 8μg/mL.结论小鼠给予含马兜铃酸A相同剂量的青木香和冠心苏合胶囊后,冠心苏合胶囊中马兜铃酸A的Cmax明显低于青木香中的Cmax,说明复方配伍作用可减少马兜铃酸A的吸收.
目的研究青木香及複方製劑冠心囌閤膠囊中馬兜鈴痠A在小鼠體內的藥動學特點及小鼠在ig給予含相同量馬兜鈴痠A的青木香和冠心囌閤膠囊後,馬兜鈴痠A的吸收、分佈規律的差異.方法採用RP-HPLC法測定血漿中馬兜鈴痠A的量.色譜條件:色譜柱為DiamonsilTMC18柱(250 mm×4.6 mm,5 μm),流動相為甲醇-水-冰醋痠(72:27 :1),體積流量為1.0 mL/min,檢測波長為315 nm,柱溫為20℃.結果藥動學實驗結果顯示小鼠分彆ig給予青木香和冠心囌閤膠囊(相噹于2.5 mg/kg馬兜鈴痠A)後,其體內的藥動學房室模型均符閤一室模型,青木香中馬兜鈴痠A主要藥動學參數:t1/2ka、t1/2ke,tmax、AUC、Cmax分彆為5.103 min、43.63 min、17.89 min、80.45(μg·min)/mL、0.916 8 μg/mL;冠心囌閤膠囊中相應的參數分彆為5.294 min、43.50min、18.32 min、33.08(μg·min)/mL、0.381 8μg/mL.結論小鼠給予含馬兜鈴痠A相同劑量的青木香和冠心囌閤膠囊後,冠心囌閤膠囊中馬兜鈴痠A的Cmax明顯低于青木香中的Cmax,說明複方配伍作用可減少馬兜鈴痠A的吸收.
목적연구청목향급복방제제관심소합효낭중마두령산A재소서체내적약동학특점급소서재ig급여함상동량마두령산A적청목향화관심소합효낭후,마두령산A적흡수、분포규률적차이.방법채용RP-HPLC법측정혈장중마두령산A적량.색보조건:색보주위DiamonsilTMC18주(250 mm×4.6 mm,5 μm),류동상위갑순-수-빙작산(72:27 :1),체적류량위1.0 mL/min,검측파장위315 nm,주온위20℃.결과약동학실험결과현시소서분별ig급여청목향화관심소합효낭(상당우2.5 mg/kg마두령산A)후,기체내적약동학방실모형균부합일실모형,청목향중마두령산A주요약동학삼수:t1/2ka、t1/2ke,tmax、AUC、Cmax분별위5.103 min、43.63 min、17.89 min、80.45(μg·min)/mL、0.916 8 μg/mL;관심소합효낭중상응적삼수분별위5.294 min、43.50min、18.32 min、33.08(μg·min)/mL、0.381 8μg/mL.결론소서급여함마두령산A상동제량적청목향화관심소합효낭후,관심소합효낭중마두령산A적Cmax명현저우청목향중적Cmax,설명복방배오작용가감소마두령산A적흡수.
Objective To study the pharmacokinetics of aristolochic acid A in Radix Aristolochiae and the compound preparation of Guanxinsuhe Capsule in mice in vivo after single-dose oral administration and observe the difference of aristolochic acid A absorption and distribution. Methods Aristolochic acid A assay was performed by RP-HPLC on a Waters apparatus with a DiamonsilTM C18 column (250 mm × 4.6mm, 5 μm), a mobil phase: a mixture of methanol-water-acetic acid (72: 27 : 1), flow rate: 1.0 mL/min, detection wavelength: 315 nm, and column temperature: 20 ℃. Results Mice were given Radix Aristolochiae and Guanxinsuhe Capsule by ig at the same level of 2. 5 mg/kg of aristolochic acid A, respectively, which were suspended in 0. 3% CMC-Na solution. Plasma concentrations were determined by RPHPLC. After single-dose ig administration of Radix Aristolochiae or Guanxinsuhe Capsule to mice, the mean plasma concentration-time courses of aristolochic acid A obtained fitted the one-compartment model.The main pharmacokinetic parameters of aristolochic acid A in Radix Aristolochiae, t1/2ka, t1/2 ke, tmax,AUC, Cmax are 5. 103 min, 43. 63 min, 17.89 min, 80. 45 (μg · min)/mL, and 0. 916 8 μg/mL; the rela tive pharmacokinetic parameters in Guanxinsuhe Capsule are 5. 294 min, 43.50 min, 18. 32 min, 33.08(μg · min)/mL, and 0. 381 8 μg/mL. Conclusion The Cmax of aristolochic acid A in Guanxinsuhe Capsule is significantly less than that in Radix Aristolochiae, which indicates that the compound compability could decrease the absorption of aristolochiae acid A.